Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Atopic Dermatitis
NCT02594098Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in atopic dermatitis (AD), sponsored by Icahn School of Medicine at Mount Sinai. Started Nov 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02594098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594098.